This issue brief examines how the Trump Administration proposals to lower drug costs described in the Administration’s Blueprint affect Medicaid. These include proposals to change the Medicaid Drug Rebate Program, as well as other approaches.
Featured Prescription Drugs Resources
This slideshow looks at past, present and future trends in prescription drug spending with a focus on the role of specialty drugs.
Slideshow See More
Related Prescription Drugs Resources
- Kaiser Health News Coverage of Prescription Drug Issues
- How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid?
- Medicare Part D in 2018: The Latest on Enrollment, Premiums, and Cost Sharing
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- Summary of Recent and Proposed Changes to Medicare Prescription Drug Coverage and Reimbursement
- Kaiser Health Tracking Poll – March 2018: Views on Prescription Drug Pricing and Medicare-for-all Proposals
- 10 Essential Facts About Medicare and Prescription Drug Spending
- No Limit: Medicare Part D Enrollees Exposed to High Out-of-Pocket Drug Costs Without a Hard Cap on Spending
- Public Opinion on the Use and Abuse of Prescription Opioids
- Searching for Savings in Medicare Drug Price Negotiations
- Medicaid’s Most Costly Outpatient Drugs
- Retail Prescription Drugs Filled at Pharmacies (Annual per Capita)
- 2017 Employer Health Benefits Survey
This slideshow draws on recent Kaiser Family Foundation poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
Slideshow See More
- view as grid
- view as list
Three firms Account for Over Half of All Medicare Part D Enrollees in 2018, and Pending Mergers Would Further Consolidate the Marketplace
In 2018, three Medicare Part D plan sponsors—UnitedHealth, Humana, and CVS Health—account for more than half of the program’s 43 million Part D enrollees (55%) and two-thirds of all stand-alone drug plan enrollees, indicating a marketplace that is dominated by a handful of major insurers, according to a new Kaiser…
This brief about the 2018 Medicare Part D marketplace analyzes the latest data on Medicare drug coverage and trends over time, including both stand-alone prescription drug plans and Medicare Advantage drug plans. The analysis focuses on enrollment, premiums, cost sharing, and the low-income subsidy.
The latest KFF Health Tracking Poll finds health care ranking among the top issues voters want to hear candidates talk about during their congressional campaigns, with health care cost ranking as the top health care issue for voters across partisanship. However, for many voters, including one-third of Republican voters, a candidate’ position on President Trump will make the biggest difference in how they vote in 2018. This month’s poll also takes an in-depth look at voters who say a candidate’s position on health care will be the “most important factor” in their 2018 congressional vote choice, otherwise known as “health care voters.”
Six Months ahead of the Midterm Elections, Democratic and Republican Voters’ Views about President Trump Outweigh their Views on Issues, Including Health Care
Who are the “Health Care Voters”? Mostly Women, and Mostly Planning to Vote Democratic As primary season for the 2018 midterm elections heats up, the latest Kaiser Family Foundation poll suggests the elections are shaping up more as a referendum on President Trump than on health care or any other…
In response to higher drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing Medicare to negotiate the price of prescription drugs. This issue brief provides a short history of this proposal, describes various approaches, and assessments of their potential savings from the Congressional Budget Office (CBO), and considers the prospects for action in the future.
The cost of prescription drugs remains a hot-button issue for consumers and policymakers. The vast majority of the public views drug prices as unreasonable, and one in four people taking prescription drugs report difficulty affording their medication. Recently, the Trump Administration, Congress and state and federal policy makers have focused renewed…
Analysis: Cost of Treating Opioid Addiction Rose Rapidly for Large Employers as the Number of Prescriptions Has Declined
A new Kaiser Family Foundation analysis finds that while the use of prescription opioids among people with employer-based health coverage has declined to its lowest levels in over a decade, the cost of treating addiction and overdoses has increased sharply. The annual cost of treating opioid addiction and overdose –…
This chart series highlights 5 key things to know about the intersection of the nation’s HIV and opioid epidemics.